Amundi Has $1.86 Billion Stock Holdings in Johnson & Johnson $JNJ

Key Points

• Amundi reduced its stake in Johnson & Johnson by 2.8%, selling 330,349 shares in the first quarter, now owning approximately 11.6 million shares valued at around $1.86 billion.
• Citigroup and UBS Group both raised their price targets for Johnson & Johnson, with Citigroup increasing it to $200 and UBS raising it to $190, indicating strong interest from analysts.
• Johnson & Johnson recently announced a quarterly dividend of $1.30 per share with a yield of 2.9%, reflecting a healthy dividend payout ratio of 55.61%.

Amundi lowered its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 2.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,599,834 shares of the company's stock after selling 330,349 shares during the period. Johnson & Johnson accounts for approximately 0.7% of Amundi's portfolio, making the stock its 19th largest position. Amundi owned 0.48% of Johnson & Johnson worth $1,858,057,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in JNJ. Ancora Advisors LLC lifted its holdings in shares of Johnson & Johnson by 0.5% in the first quarter. Ancora Advisors LLC now owns 262,034 shares of the company's stock valued at $43,456,000 after purchasing an additional 1,335 shares in the last quarter. Aprio Wealth Management LLC grew its position in Johnson & Johnson by 40.8% during the first quarter. Aprio Wealth Management LLC now owns 11,340 shares of the company's stock valued at $1,881,000 after acquiring an additional 3,285 shares during the period. 5th Street Advisors LLC purchased a new position in shares of Johnson & Johnson in the 1st quarter worth about $234,000. Adage Capital Partners GP L.L.C. lifted its position in Johnson & Johnson by 36.8% during the first quarter. Adage Capital Partners GP L.L.C. now owns 1,278,427 shares of the company's stock valued at $212,014,000 after buying an additional 343,625 shares in the last quarter. Finally, Promethium Advisors LLC raised its position in Johnson & Johnson by 14.5% in the first quarter. Promethium Advisors LLC now owns 22,864 shares of the company's stock valued at $3,792,000 after purchasing an additional 2,902 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Performance

NYSE:JNJ traded down $0.57 during mid-day trading on Friday, hitting $178.20. The stock had a trading volume of 9,733,095 shares, compared to its average volume of 8,970,201. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The company has a 50 day simple moving average of $168.06 and a 200-day simple moving average of $160.60. The stock has a market capitalization of $429.15 billion, a price-to-earnings ratio of 19.06, a P/E/G ratio of 2.27 and a beta of 0.40. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. During the same quarter last year, the company earned $2.82 EPS. Johnson & Johnson's quarterly revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 2.9%. Johnson & Johnson's dividend payout ratio is currently 55.61%.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on JNJ shares. Wall Street Zen downgraded shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research note on Friday, July 18th. Leerink Partners downgraded shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and decreased their price target for the stock from $169.00 to $153.00 in a research report on Tuesday, May 13th. Piper Sandler reaffirmed an "overweight" rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Citigroup upped their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the company a "buy" rating in a research note on Thursday, August 21st. Finally, Barclays lifted their target price on Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, Johnson & Johnson has an average rating of "Moderate Buy" and a consensus price target of $176.29.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.